Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Research: Key Market Segments And Long-Term Growth Outlook

 

The Business Research Company’s 2026 market reports provide deeper strategic insights through market attractiveness analysis, total addressable market assessment, company scoring, interactive Excel dashboards, enhanced supply chain analysis, emerging startup insights, and key product overviews.
 
 What Could The Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Be Worth By 2030?
 The next-generation adeno-associated virus (AAV) gene therapy delivery market size has grown rapidly in recent years. It will grow from $4.96 billion in 2025 to $5.93 billion in 2026 at a compound annual growth rate (CAGR) of 19.5%. The growth in the historic period can be attributed to increasing gene therapy research activities, rising prevalence of rare genetic disorders, growing investment in biotechnology innovation, expanding clinical trials for AAV-based therapies, increasing demand for targeted therapeutic approaches.
 
 The next-generation adeno-associated virus (AAV) gene therapy delivery market size is expected to see rapid growth in the next few years. It will grow to $11.91 billion in 2030 at a compound annual growth rate (CAGR) of 19.1%.The growth in the forecast period can be attributed to growing adoption of personalized gene therapies, increasing development of advanced AAV vector engineering platforms, rising commercialization of gene therapy products, expanding research in precision medicine applications, growing demand for improved safety and efficacy of genetic treatments. Major trends in the forecast period include increasing adoption of engineered aav capsid technologies for targeted gene delivery, growing development of immune response reduction strategies in aav therapies, rising demand for durable and precise gene expression platforms, expanding applications of next generation aav vectors in rare disease treatments, increasing focus on scalable manufacturing processes for advanced gene therapy vectors.
 
 Get Your Free Report Sample
 https://www.thebusinessresearchcompany.com/sample_request?id=91167747&type=smp&name=Next-Generation%20Adeno-Associated%20Virus%20%28AAV%29%20Gene%20Therapy%20Delivery%20Market%20Report%202026&utm_source=Blogger&utm_medium=Free&utm_campaign=Sep_PR
 
 What Are The Main Drivers Behind Growth In The Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market?
 The increasing adoption of targeted gene therapies is expected to propel the growth of the next-generation adeno-associated virus gene therapy delivery market going forward. Targeted gene therapies refer to a form of treatment that delivers genetic material to specific cells or tissues in the body to correct or modify disease-causing genes while minimizing effects on non-target cells. Increasing adoption of targeted gene therapies is due to advances in gene delivery technologies that improve precision, safety, and efficiency in delivering therapeutic genes directly to specific cells or tissues. Increasing adoption of targeted gene therapies drives demand for more precise, efficient, and tissue-specific delivery systems, thereby accelerating innovation and refinement in next-generation adeno-associated virus (AAV) gene therapy delivery platforms. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, in the fourth quarter of 2023, the number of gene therapies in Phase III rose by 10% compared to the previous quarter, representing the first increase since the third quarter of 2022. Therefore, the increasing adoption of targeted gene therapies is driving the growth of the next-generation adeno-associated virus gene therapy delivery market.
 
 Who Shapes The Competitive Landscape Of The Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market?
 Major companies operating in the next-generation adeno-associated virus (aav) gene therapy delivery market are Pfizer Inc., Novartis AG, Bayer AG, Astellas Pharma Inc., Sarepta Therapeutics Inc., Adverum Biotechnologies Inc., uniQure N.V., REGENXBIO Inc., Rocket Pharmaceuticals Inc., MeiraGTx Holdings plc, 4D Molecular Therapeutics, Voyager Therapeutics Inc., Taysha Gene Therapies Inc., Passage Bio Inc., Solid Biosciences Inc., Affinia Therapeutics Inc., Encoded Therapeutics Inc., Capsida Biotherapeutics Inc, AAVantgarde Bio S.r.l., VectorY Therapeutics B.V., Ring Therapeutics, Dyno Therapeutics Inc., Généthon, Sangamo Therapeutics Inc. 
 
 What Emerging Developments Are Influencing The Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market?
 Major companies operating in the next-generation adeno-associated virus gene therapy delivery market are focusing on developing innovative solutions, such as engineered capsids to improve transduction efficiency, reduce required dosing, and enhance overall safety and therapeutic efficacy. Engineered capsids are genetically modified protein shells of adeno-associated viruses (AAVs) designed to improve gene delivery by enhancing tissue targeting, increasing transduction efficiency, and reducing immune recognition. For instance, in May 2026, Affinia Therapeutics, a US-based biotechnology company, presented new preclinical and translational data at a major gene and cell therapy conference, highlighting advances in its AAV gene therapy platform. The update showcased progress in capsid engineering, manufacturing scalability, and clinical trial design aimed at improving targeted gene delivery efficiency. Its lead candidate, AFTX-201, was emphasized for its potential in treating BAG3-associated dilated cardiomyopathy through enhanced cardiac-specific gene expression using a proprietary AAV vector.
 
 What Are The Major Segments Defining The Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market?
 The next-generation adeno-associated virus (aav) gene therapy delivery market research report is one of a series of new reports from The Business Research Company that provides next-generation adeno-associated virus (aav) gene therapy delivery market statistics, including next-generation adeno-associated virus (aav) gene therapy delivery industry global market size, regional shares, competitors with a next-generation adeno-associated virus (aav) gene therapy delivery market share, detailed next-generation adeno-associated virus (aav) gene therapy delivery market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation adeno-associated virus (aav) gene therapy delivery industry. This next-generation adeno-associated virus (aav) gene therapy delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
 
 Access The Full Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report
 https://www.thebusinessresearchcompany.com/report/next-generation-adeno-associated-virus-aav-gene-therapy-delivery-market-global-report?utm_source=Blogger&utm_medium=Free&utm_campaign=Sep_PR
 
 Which Geographic Region Could Become The Growth Leader For The Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market?
 North America was the largest region in the next-generation adeno-associated virus (AAV) gene therapy delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation adeno-associated virus (AAV) gene therapy delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: marketing@tbrc.info
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company